Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis ; volume:8 ; number:1 ; day:1 ; month:2 ; year:2018 ; pages:1-10 ; date:12.2018
Scientific reports ; 8, Heft 1 (1.2.2018), 1-10, 12.2018
- Creator
-
Hsieh, Meng-Chiao
- Contributor
-
Wu, Chun-Feng
Chen, Chun-Wei
Shi, Chung-Sheng
Huang, Wen-Shih
Kuan, Feng-Che
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-19835-8
- URN
-
urn:nbn:de:1111-2018041617533
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hsieh, Meng-Chiao
- Wu, Chun-Feng
- Chen, Chun-Wei
- Shi, Chung-Sheng
- Huang, Wen-Shih
- Kuan, Feng-Che
- SpringerLink (Online service)
Other Objects (12)
![398 - The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies [Poster abstract]](/assets/placeholder/searchResultMediaUnknown.png)
398 - The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies [Poster abstract]
Monoclonal antibodies
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Monoclonal antibodies in transplantation
Glycoengineering of Monoclonal Antibodies
Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study
Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
Clinical relevance of new monoclonal antibodies
Establishment of anti-mesothelioma monoclonal antibodies
Mechanically interlocked functionalization of monoclonal antibodies
Monoclonal antibodies for migraine: an update
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
398 - The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies [Poster abstract]
Monoclonal antibodies
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Monoclonal antibodies in transplantation
Glycoengineering of Monoclonal Antibodies
Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study
Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
Clinical relevance of new monoclonal antibodies
Establishment of anti-mesothelioma monoclonal antibodies
Mechanically interlocked functionalization of monoclonal antibodies
Monoclonal antibodies for migraine: an update
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
398 - The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies [Poster abstract]
Monoclonal antibodies
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Monoclonal antibodies in transplantation
Glycoengineering of Monoclonal Antibodies
Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study
Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
Clinical relevance of new monoclonal antibodies
Establishment of anti-mesothelioma monoclonal antibodies
Mechanically interlocked functionalization of monoclonal antibodies
Monoclonal antibodies for migraine: an update